SSI PROTECTION

Simplified
In just 60 seconds

Profend™
Nasal Decolonization Kit

The PVP-iodine swabstick preferred by >90% of clinicians

- Easy application by clinical staff assures compliance
- Quick treatment saves time
- Neat, dry-handle design minimizes mess
- Resistance-free efficacy supports antibiotic stewardship
Easy-to-use, pre-saturated, 10% PVP-iodine swabstick

Snap & Swab
Nasal decolonization

Easy application
Small nasal swab offers enhanced patient comfort
Preferred by clinicians over competitive PVP-iodine products
Applied by clinical staff for assured compliance

Quick, effective treatment
60-second treatment—up to two-and-a-half times faster than other PVP-iodine products
Faster time to full efficacy than antibiotics, with no evidence of Staphylococcus aureus/Methicillin-resistant Staphylococcus aureus (MRSA) resistance
Kills 99.7% of S. aureus at 1 hour and 99.9% at 12 hours

Neat, dry-handle design
Neat, dry-handle design minimizes mess vs other nasal decolonization products

Proactively defend your patients and facility today...
Easy, quick, neat, effective protection

Key advantages against antibiotics and alcohol

<table>
<thead>
<tr>
<th>Nasal Decolonization Agent</th>
<th>Profend™</th>
<th>Mupirocin</th>
<th>Nozin®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assured compliance as clinician applies</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Supports antibiotic stewardship</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Mean S. aureus kill rate after 1 application: **99.9% at 12 hours**<sup>2</sup> vs 82% with Nozin after 3 applications<sup>3</sup>

Patient-preferred solution vs mupirocin<sup>4</sup>

In a study, 1,679 patients were interviewed after receiving nasal decolonization via PVP-iodine or mupirocin...

96.6% of patients receiving PVP-iodine reported a pleasant or neutral experience (<i>P</i>&lt;0.0001)

- Among patients self-administering mupirocin, 38.8% reported an unpleasant or very unpleasant experience
- Those receiving PVP-iodine reported significantly fewer adverse events than patients self-administering nasal mupirocin (<i>P</i>&lt;0.01)

Preferred over other nasal PVP-iodine products by >90% of clinicians<sup>1*</sup>

<table>
<thead>
<tr>
<th>Agree or Strongly Agree</th>
<th>Profend™</th>
<th>3M™</th>
<th>Medline®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is easily administered due to simple and intuitive design</td>
<td>93%</td>
<td>47%</td>
<td>33%</td>
</tr>
<tr>
<td>Increases likelihood of compliance due to ease of application</td>
<td>87%</td>
<td>40%</td>
<td>27%</td>
</tr>
<tr>
<td>Enables mess-free application due to container design</td>
<td>93%</td>
<td>47%</td>
<td>20%</td>
</tr>
</tbody>
</table>

Fast and efficient: Compared with competitors...

80% agreed Profend Nasal Decolonization Kit application time is significantly less

87% agreed Profend Nasal Decolonization Kit offers a more efficient application process

100% of clinicians felt their patients would prefer...
Decolonize before all surgeries

*S. aureus/MRSA* poses a significant challenge in the operating room, especially for high-risk surgeries such as cardiac or orthopedic procedures.

**SSI: Widespread and costly**

- 290,000 events/year
- 22% of all HAI
- Accounts for >90,000 readmissions/year

**20.7% & 6.7% mortality rates in MRSA SSI and S. aureus SSI**

- 77% of SSI-related deaths were directly attributable to the SSI

**Up to 19% higher cost due to MRSA SSI vs S. aureus SSI**

- Up to $10 billion estimated annual cost, with up to $60,000 added burden/incident

**A leading cause is right under your nose**

- Up to 30% of healthy adults are nasally colonized
- An increasingly complex threat: In 1990, <2% of *S. aureus* strains were methicillin-resistant; by 2002, that percentage rose to 42%

- 80% of *S. aureus* SSIs come from the patient’s own nasal flora

- Up to 9x increase in SSI risk due to nasal colonization

- MRSA colonization is associated with a higher risk of both MRSA SSI and SSI overall

**The burden of *S. aureus/MRSA* outside the operating room**

- High-risk settings include the ICU, hemodialysis unit, and long-term care
- Responsible for 12% of CLABSIs and 24% of VAP
- Elevated costs of care: MRSA screening and contact precautions

**Proactively defend against SSIs: 60% of SSIs are preventable**
Snap & Swab
Nasal decolonization

Easy-to-use, pre-saturated PVP-iodine swabstick

- Effective 10% PVP-iodine solution supports antibiotic stewardship
- Kills 99.7% of S. aureus at 1 hour and 99.9% at 12 hours2
- Ideal for S. aureus- and MRSA-colonized patients in the surgical unit, ICU, and other areas of the hospital2,22

Proactively defend your patients and facility today — speak with your PDI sales representative or visit pdihc.com/Profend

The latest infection prevention innovation from PDI: a multi-generational, family-owned company dedicated to helping you Be The Difference® in fighting infection and creating more happy homecomings for your patients.